Can I take Mounjaro if a parent had papillary thyroid cancer?

The contraindication on the label names medullary thyroid carcinoma and MEN 2 only. Papillary thyroid cancer is a different disease and is not listed. Tell your prescriber the exact diagnosis in your family so they can check the record before writing the prescription.

Do I need a baseline thyroid ultrasound before I start?

The prescribing information does not require baseline imaging. It asks prescribers to take a personal and family history for medullary thyroid carcinoma and MEN 2. Ask your clinician about imaging if you already have an unexplained neck lump or a known thyroid nodule.

My calcitonin came back slightly high. Should I stop the drug?

Do not stop on your own. The label says serum calcitonin has low test specificity, so mildly raised values often have other causes. It also notes that people with medullary thyroid carcinoma usually have values above 50 ng/L. Let your clinician interpret the result.

Did the rat tumors happen at doses people actually take?

The boxed warning says the rat C-cell tumors occurred at clinically relevant exposures. The effect grew with both dose and treatment duration. A separate six-month study in rasH2 transgenic mice found that tirzepatide was not tumorigenic at the doses tested.

Were any thyroid tumors seen in the Mounjaro clinical trials?

The prescribing information reports the C-cell tumor findings from animal work, not from the human trial program. Short trials cannot rule out a slow-growing cancer. That is why the label keeps the warning while calling the human relevance undetermined.

Does Mounjaro Raise Your Risk Of Thyroid Cancer?

The short answer: No human study has shown that Mounjaro causes thyroid cancer. Tirzepatide, the active drug in Mounjaro, carries an FDA boxed warning because it caused thyroid C-cell tumors in rats. The label itself says the human relevance of those rodent tumors has not been determined. The label does rule the drug out for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

What does the Mounjaro boxed warning actually say?

The FDA prescribing information for Mounjaro opens with a boxed warning headed "RISK OF THYROID C-CELL TUMORS." A boxed warning is the strongest warning the FDA puts on a drug label.

The warning has three parts. The first describes the animal data: "In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures."

The second part states the limit of that finding: "It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined."

The third part names who cannot take the drug. Mounjaro "is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)." The warning also tells prescribers to counsel patients on the symptoms of thyroid tumors.

A boxed warning is not proof of harm in people. It flags a serious potential risk that the prescriber and the patient should weigh together. For the rest of the label's safety picture, see our complete guide to Mounjaro.

Why does the warning come from rodent studies?

Section 13.1 of the label describes the animal carcinogenicity work. In a two-year rat study, the label reports "a statistically significant increase in thyroid C-cell adenomas" in males and females. It also reports a significant increase in "thyroid C-cell adenomas and carcinomas combined" in males and females at every dose examined.

The mouse result went the other way. In a six-month carcinogenicity study in rasH2 transgenic mice, the label states that tirzepatide "was not tumorigenic" at the doses tested.

Rodent findings do not transfer automatically to people. Regulators treat a positive rat carcinogenicity signal as a reason for caution until human data settle the question. That is why the FDA required a warning and a contraindication instead of blocking approval.

How is medullary thyroid cancer different from papillary thyroid cancer?

This distinction matters. Most thyroid cancer you hear about is a different disease from the one named in the warning.

The American Thyroid Association reports that papillary thyroid cancer "is the most common type, making up about 70% to 80% of all thyroid cancers." Follicular cancer accounts for about 10% to 15%. Medullary thyroid cancer accounts for approximately 2%, and anaplastic cancer for less than 2%.

Papillary and follicular cancers start in the follicular cells that make thyroid hormone. Medullary thyroid cancer starts in the C cells, which make the hormone calcitonin. Those C cells are the cells that grew tumors in the rat studies.

MTC is also the type most often inherited. The ATA notes that inherited MTC occurs in up to 25% of diagnoses and involves a mutation in the RET proto-oncogene. The National Cancer Institute links inherited MTC to familial medullary thyroid cancer, MEN2A, and MEN2B. For broader background on thyroid disease, see thyroid.md.

What have human studies found so far?

The human evidence is mixed, and it has moved toward reassurance. Most of it covers the GLP-1 drug class rather than tirzepatide alone, because tirzepatide only reached the market in 2022.

French national data (2023). A nested case-control study in Diabetes Care used the French SNDS insurance database. It matched 2,562 thyroid cancer cases with 45,184 controls. For one to three years of GLP-1 use, the adjusted hazard ratio was 1.58 (95% CI 1.27 to 1.95) for all thyroid cancer. For medullary thyroid cancer it was 1.78 (95% CI 1.04 to 3.05).
Scandinavian cohort (2024). A BMJ study followed 145,410 GLP-1 users in Denmark, Norway, and Sweden for a mean of 3.9 years. Against DPP-4 inhibitor users, the hazard ratio for thyroid cancer was 0.93 (95% CI 0.66 to 1.31). Medullary cases were rare: 4 in the GLP-1 group and 11 in the comparator group, a hazard ratio of 1.19 (95% CI 0.37 to 3.86).
Six-country study (2025). The American Thyroid Association described a study of 92,497 GLP-1 users against 2,484,408 DPP-4 inhibitor users across six countries. The authors "found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8-3.0 years."

Adverse event reports are weaker evidence. An analysis of the FDA Adverse Event Reporting System published in 2025 found a reporting odds ratio of 2.09 for tirzepatide and thyroid cancer. The authors state that FAERS data "cannot establish causation," because the database has no control group and reporting rises with publicity.

Two limits apply to all of this work. Follow-up is short next to how slowly thyroid cancer usually grows. Most participants also had type 2 diabetes, so the numbers may not carry over to people using these drugs only for weight loss. If you are weighing options in this class, our Mounjaro versus Ozempic comparison covers the shared class warning.

Should you get calcitonin testing or a thyroid ultrasound?

The label does not recommend either as routine. It states: "Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO."

The label also explains why. Such monitoring "may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease." In plain terms, a mildly raised calcitonin result usually means something other than cancer, and thyroid nodules are common in healthy adults.

Testing still has a role when something specific prompts it. The label notes that significantly elevated calcitonin values may indicate MTC, and that people with MTC usually have values above 50 ng/L. It also says patients with thyroid nodules found on physical examination or neck imaging should be evaluated further. That call belongs to your clinician, not to a fixed schedule.

Which symptoms warrant a call to your doctor?

The label tells prescribers to inform patients about the symptoms of thyroid tumors. It names four:

A mass or lump in the neck
Trouble swallowing (dysphagia)
Shortness of breath (dyspnea)
Persistent hoarseness

None of these is specific to cancer. Hoarseness follows a common cold. Neck lumps are often benign nodules or swollen lymph nodes. The point is not alarm. It is that these four should be checked rather than waited out, especially if they last several weeks.

Nausea, reflux, and the other common Mounjaro complaints are a separate matter. Our guide to managing Mounjaro side effects covers those.

The bottom line

Mounjaro carries a boxed warning for thyroid C-cell tumors based on rat studies, and the FDA label says the human relevance has not been determined. If you have a personal or family history of medullary thyroid carcinoma or MEN 2, the label rules the drug out for you. If you do not, the largest human cohort studies so far have not found a clear increase in thyroid cancer risk, though follow-up remains short. Routine calcitonin testing and thyroid ultrasound are not recommended. Report a neck lump, trouble swallowing, shortness of breath, or lasting hoarseness to your clinician.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber or an endocrinologist about your own thyroid and family history before you start or continue Mounjaro.